Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter study
Phytomedicine · 2024-04 · 126 · 155264
DOI: 10.1016/j.phymed.2023.155264 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Phytomedicine, 2024-04. Verfasst von Xingling He und 19 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China; Lingnan Medical Research Center, Guangzhou Universi…. Hauptthemen laut MEDLINE: Angina, Stable. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Program Key Projects, Traditional Chinese Medicine Bureau of Guangdong Province.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Stable angina pectoris (SAP) is a clinical condition characterized by reversible and temporary myocardial ischemia and hypoxia. A majority of SAP patients also experience depressive disorders, which adversely affect their disease prognosis and overall quality of life. However, the clinical utility of existing antidepressants is constrained by their side effects. Ginkgo biloba dropping pill (GBDP), a Chinese patented medication, has demonstrated efficacy in the treatment of both coronary heart disease and mental disorders. This prospective, randomized, double-blind, multicenter clinical trial aimed to assess the effectiveness and safety of GBDP as an adjuvant therapy for SAP complicated by depression. METHODS: Participants were randomly assigned in a 1:1 ratio to receive either GBDP or a placebo (5 pills, three times a day) in addition to standard therapy for a duration of 12 weeks. The Seattle Angina Questionnaire (SAQ) was administered every 4 weeks during the treatment, and angina event frequency was assessed weekly. The 36-item Short-Form (SF-36) and Hamilton Depression Scale (HAMD) scores were measured both before and after the treatment. RESULTS: Out of the 72 patients, 68 (n = 34 per group) completed the entire study. At the first visit (4 weeks ± 3 days), the SAQ-Angina Stability score in the GBDP group was significantly higher than that in the placebo group (p 0.05). By the endpoint, each subcategory score of SF-36 in the GBDP group exhibited significant improvement compared to baseline (p 0.05). CONCLUSION: In patients with SAP complicated by depression, GBDP, when combined with standard treatment, rapidly and safely alleviates angina pectoris symptoms. It demonstrates therapeutic potential in enhancing the quality of life and alleviating depressive symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
- The Second Affiliated Hospital of Guizhou University of Chinese Medicine, Department of Cardiology, Guizhou 550001, China.
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Drug Clinical Trial Institution, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Phase I Cli…
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Geriatrics, Guangzhou 510405, China.
- Shenzhen Luohu Hospital of Traditional Chinese Medicine, Department of Geriatrics, Shenzhen, 518001, China.
- Shenzhen Qianhai Shekou Free Trade Zone Hospital, Department of Traditional Chinese Medicine, Shenzhen, 518067, China.
Förderung
- National Natural Science Foundation of China
- Guangzhou Science and Technology Program Key Projects
- Traditional Chinese Medicine Bureau of Guangdong Province
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
- Natural Science Foundation of Guangdong Province
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholars
Zitieren
APA
He, X., Liu, D., Ni, S., Li, Z., Li, S., Wu, T., Dong, X., Zhang, X., Tang, Y., Ling, Y., Liao, H., Kang, J., Li, Y., Wu, H., Luo, J., Wan, X., Zhang, D., Lu, L., Long, W., & Yang, Z. (2024). Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter study. Phytomedicine, 126, 155264. https://doi.org/10.1016/j.phymed.2023.155264
Vancouver
He X, Liu D, Ni S, Li Z, Li S, Wu T, et al. Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter study. Phytomedicine. 2024;126:155264. doi:10.1016/j.phymed.2023.155264
BibTeX
@article{He2024,
author = {He, Xingling and Liu, Donghua and Ni, Shihao and Li, Ziru and Li, Sijing and Wu, Tingchun and Dong, Xiaoming and Zhang, Xiaojiao and Tang, Yaqin and Ling, Yan and Liao, Huili and Kang, Jinhua and Li, Yue and Wu, Hongyan and Luo, Jing and Wan, Xianming and Zhang, Dan and Lu, Lu and Long, Wenjie and Yang, Zhongqi},
title = {Efficacy and safety evaluation of Ginkgo biloba dropping pill (GBDP) on stable angina pectoris complicated with depression: A placebo-controlled, randomized, double-blind, multicenter study},
journal = {Phytomedicine},
year = {2024},
volume = {126},
pages = {155264},
doi = {10.1016/j.phymed.2023.155264}
}
EUVIMED